PD-1 inhibitors

GLP-1s set to take drug sales throne from PD-1 inhibitors in 2024
Medical Marketing and Media
Wed, 03/20/24 - 09:43 pm
GLP-1 agonist
PD-1 inhibitors
Wegovy
Ozempic
Zepbound
Mounjaro
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection
Fierce Pharma
Wed, 02/9/22 - 10:56 am
Eli Lilly
Innovent
Tyvyt
PD-1 inhibitors
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Wed, 12/30/20 - 10:53 am
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
BioCentury
Wed, 07/3/19 - 12:07 am
Zai Lab
China
PD-1 inhibitors
Incyte
Fast moving Chinese regulators wave third homegrown PD-1 to market
Endpoints
Fri, 05/31/19 - 11:51 pm
China
Jiangsu Hengrui Medicine
PD-1 inhibitors
Dana-Farber’s 4-year legal battle shines a light on the origins of PD-1 research — forcing a reckoning on who pioneered the landmark cancer breakthrough
Endpoints
Sun, 05/19/19 - 04:00 pm
Dana-Farber
drug development
PD-1 inhibitors
Can Sanofi compete in lung cancer? With I-O med cemiplumab, it’s aiming for third
Fierce Pharma
Thu, 06/14/18 - 11:24 am
Sanofi
PD-1 inhibitors
cemiplumab
lung cancer
Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint
Endpoints
Mon, 04/30/18 - 10:08 am
Regeneron
Sanofi
PD-1 inhibitors
FDA
cemiplimab
AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints
Endpoints
Fri, 02/2/18 - 09:18 am
AstraZeneca
PD-1 inhibitors
asthma
tralokinumab
lebrikizumab
Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
Endpoints
Wed, 10/25/17 - 09:44 am
Incyte
PD-1 inhibitors
Macrogenics
MGA012
Bristol-Myers to test Opdivo with Nektar drug for several cancers
Yahoo/Reuters
Tue, 09/27/16 - 10:47 am
Bristol-Myers Squibb
Opdivo
Nektar
NKTR-214
PD-1 inhibitors
cancer
U.S. regulator says too many drugmakers chasing same cancer strategy
Yahoo/Reuters
Fri, 06/10/16 - 08:53 am
FDA
oncology
ASCO 2016
Merck
Bristol-Myers Squibb
PD-1 inhibitors
AstraZeneca ties up with little Mirati on another PD-L1 combo trial
Fierce Biotech
Thu, 08/6/15 - 08:27 am
AstraZeneca
PD-1 inhibitors
durvalumab
MedImmune
Mirati Therapeutics
Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazing
Fierce Pharma
Fri, 05/22/15 - 12:04 pm
Merck
Keytruda
Bristol-Myers Squibb
Europe
PD-1 inhibitors
New cancer drugs "vastly overestimated", says contrarian analyst
Yahoo/Reuters
Tue, 03/31/15 - 12:46 pm
cancer
PD-1 inhibitors
PDL-1 inhibitors
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Merck says melanoma drug meets goal; study halted
Yahoo/Reuters
Tue, 03/24/15 - 03:11 pm
Merck
Keytruda
clinical trials
PD-1 inhibitors
Global cancer drug market to grow to $111 billion by 2020: report
Medical Marketing and Media
Tue, 02/24/15 - 05:02 pm
cancer
cancer immunotherapy
Merck
Bristol-Myers Squibb
PD-1 inhibitors